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        Introduction 
  Ceramides, ubiquitous sphingolipids in biological membranes, 
and their metabolites are receiving increasing attention in cancer 
research (  Ogretmen and Hannun, 2004  ). Besides established roles 
in apoptosis and growth arrest, novel tumor suppressor properties 
of ceramide have emerged, including effects on cellular cytoskele-
ton and motility. Exogenous short chain ceramides (C  2 -  and  C 6 -
ceramides) were shown to induce rearrangement of the F-actin 
network, cell rounding, and detachment in various cell lines, in-
cluding neuroepitheliomas, breast and cervical cancers (  Panigone 
et al., 2001  ;   Di Bartolomeo and Spinedi, 2002  ;   Hu et al., 2005  ). 
These morphological changes precede and appear to be indepen-
dent of the apoptotic signaling triggered by ceramide. Recent 
studies demonstrated that ceramide impedes surface availability 
and traffi  cking of integrin receptors; thus, interfering with cellular 
adhesion and adhesion-related survival signaling (  Panigone et al., 
2001  ;   Hu et al., 2005  ). Although these studies begin to shed light 
on the morphotropic effects of ceramide, the role of endogenous 
ceramide in these processes and the mechanisms by which cer-
amide infl  uences the actin cytoskeleton are still unclear. 
  The actin cytoskeleton and its associated proteins are 
essential players in cell motility, adhesion, and morphogenesis. 
Ezrin, a member of the ERM family, regulates cytoskeletal dy-
namics by cross-linking actin fi  laments to the plasma membrane 
(  Bretscher et al., 2002  ;   Fievet et al., 2007  ). Two cellular forms 
of ezrin have been studied: an inactive cytoplasmic form and an 
active membrane-bound form. In its inactive conformation, the 
N-terminal membrane association domain of ezrin exerts intra-
molecular masking of the actin-binding domain located at the 
C terminus. Sequential binding of the phosphoinositide PIP2 at 
the N terminus followed by phosphorylation of the C-terminal 
threonine 567 residue results in unmasking of the functional 
protein binding sites, thus allowing ezrin to associate simulta-
neously with the cytoplasmic tail of various transmembrane 
proteins and with F-actin (  Fievet et al., 2004  ). In its active form, 
ezrin promotes formation of specialized cellular protrusions 
such as lamellipodia, fi  lopodia, and microvilli, essential struc-
tures in motility and contact with other cell types. 
 Effectors of ceramide signaling have been implicated in regu-
lating cellular motility. In particular several studies have cor-
related the ceramide-activated serine/threonine phosphatase PP2A 
with decreased tumor metastasis (  Metz et al., 1996  ;   Meisinger 
et al., 1997  ).   Xu and Deng (2006  ) recently reported that loss of 
PP2A increases migration and invasion of lung cancer cells. 
T
he chemotherapeutic agent cisplatin is widely used 
in treatment of solid tumors. In breast cancer cells, 
cisplatin produces early and marked changes in cell 
morphology and the actin cytoskeleton. These changes 
manifest as loss of lamellipodia/ﬁ  lopodia and appear-
ance of membrane rufﬂ  es. Furthermore, cisplatin induces 
dephosphorylation of the actin-binding protein ezrin, and 
its relocation from membrane protrusions to the cytosol. 
Because cisplatin activates acid sphingomyelinase (ASMase), 
we investigate here the role of the ASMase/ceramide 
(Cer) pathway in mediating these morphological changes. 
We ﬁ  nd that cisplatin induces a transient elevation in 
ASMase activity and its redistribution to the plasma mem-
brane. This translocation is blocked upon over expression 
of a dominant-negative (DN) ASMase 
S508A   mutant and by 
a DN PKC    . Importantly; knockdown of ASMase protects 
MCF-7 cells from cisplatin-induced cytoskeletal changes 
including ezrin dephosphorylation. Reciprocally, exogenous 
delivery of D-e-C  16  -Cer, but not dihydro-C  16  -Cer, recapitu-
lates the morphotropic effects of cisplatin. Collectively, 
these results highlight a novel tumor suppressor property 
for Cer and a function for ASMase in cisplatin-induced 
cytoskeletal remodeling.
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of ezrin was evaluated. As expected, under basal conditions, 
  ezrin mainly localized to cellular fi  lopodia with minor cytosolic 
staining. Interestingly, treatment with cisplatin induced major 
relocation of ezrin from the cell periphery to a more cyto-
solic distribution (  Fig. 2 A  ). This observation was further cor-
roborated by a cellular fractionation approach in which the 
membrane fraction (100,000   g  ) was separated from the cyto-
solic fraction. As shown in   Fig. 2 B  , Western blotting for ezrin 
showed a marked drop in membrane-associated ezrin. (  Fig. 2 B  ). 
Collectively, these results suggest that the morphological changes 
induced by cisplatin are associated with rearrangement of 
the actin cytoskeleton and redistribution of the actin-binding 
protein, ezrin. 
 In addition to PIP2 binding, phosphorylation of the C-terminal 
threonine residue (T567) is a hallmark of ezrin activation. In its 
active form, ezrin adopts a peripheral localization that allows it 
to cross-link the plasma membrane to the cellular cytoskeleton. 
The observation that cisplatin induced cytosolic redistribution 
of ezrin prompted us to examine the phosphorylation status of 
ezrin. Using a phospho (T567) specifi  c antibody, the levels of 
active ezrin were evaluated by Western blotting after a time 
course of cisplatin treatment. The results showed that cisplatin 
caused a time-dependent dephosphorylation of ezrin seen after 
1 h and persisted up to 2 h (  Fig. 2 C  ). It is worth indicating, 
however, that total protein levels of ezrin remained unchanged. 
Dephosphorylation of ezrin at T567 was further confi  rmed 
by immunofl  uorescence after cisplatin treatment (  Fig. 2 D  ). 
Therefore, these fi  ndings indicate that the cytoskeletal changes 
induced by cisplatin are associated with inactivation of the actin-
binding protein, ezrin. 
  Cisplatin activates the 
ASMase/ceramide pathway 
  The effects of cisplatin on dephosphorylation of ezrin raised 
the possibility of activation of a serine/threonine phosphatase. 
Importantly, previous studies have shown that the bioactive lipid 
ceramide activates phosphatases in vitro and in cells (  Pettus 
et al., 2002  ). Moreover, the ASMase/ceramide pathway has 
been previously shown to be activated by cisplatin (  Levade and 
Jaffrezou, 1999  ;   Lacour et al., 2004  ). Therefore, it became im-
portant to evaluate whether the observed changes with cisplatin 
are due to modulation of sphingolipid metabolism. To that end, 
MCF-7 cells were treated with cisplatin (5   μ  g/ml) over a time 
course of 3 h, and sphingolipids were extracted by the Bligh 
Dyer technique. Mass spectrometric measurements revealed 
a transient elevation in total ceramide (twofold) within 30 min 
of cisplatin treatment (  Fig. 3 A  ). Further analysis indicated 
that this change was mainly accounted for by an increase in 
ceramide species carrying C  16   and C  24:1   acyl chains (  Fig. 3 C  ). 
Importantly, the observed changes in ceramide levels were par-
alleled by a transient drop in sphingomyelin (SM) levels (  Fig. 3 B  ). 
In particular, a major change in C  16   SM and a minor one in 
C  24:1   SM were detected by mass spectrometry after 15 min of 
cisplatin treatment (  Fig. 3 D  ). Together, this sphingolipidomic 
profi  le suggests the operation of a sphingomyelinase. 
  To investigate this possibility, in vitro sphingomyelinase 
assays were conducted using radiolabeled sphingomyelin. 
Treatment with C  2 -ceramide, a potent PP2A agonist, suppressed 
motility of cancer cells (  Xu and Deng, 2006  ). However, the under-
lying mechanisms by which PP2A affects tumor cell motility 
remain unknown. 
  To understand the molecular mechanisms by which sphingo-
lipids infl  uence cellular architecture, we investigated the effects 
of stress-induced endogenous ceramide generation in MCF-7 
breast cancer cells, using cisplatin, a chemotherapeutic agent of 
major clinical utility for treatment of breast cancer. 
  We demonstrate here that ceramide production plays 
an important role in stress-induced cytoskeletal remodeling. 
Cisplatin induced marked changes in the actin cytoskeleton, 
including dephosphorylation and cytosolic translocation of ezrin. 
Mechanistically, activation of acid sphingomyelinase (ASMase) 
is shown to be required upstream of the observed morphological 
changes. Further investigation revealed a novel association be-
tween ceramide-activated PP2A and ezrin at the plasma mem-
brane. These fi  ndings demonstrate that the ASMase/ceramide 
pathway is instrumental for cytoskeletal remodeling induced by 
chemotherapeutic interventions. 
  Results 
  Cisplatin treatment induces acute 
cytoskeletal remodeling in MCF-7 cells 
  Several studies have previously shown that anticancer drugs 
induce changes in cellular morphology (  Kruidering et al., 1998  ; 
  Bijman et al., 2006  ). As a model, we used the human mam-
mary carcinoma cells, MCF-7, originally obtained from pleural 
effusion of a patient with breast cancer. Treatment with cisplatin 
(5   μ  g/ml) caused marked morphological changes within 2 h. 
As shown in   Fig. 1 A  , the morphological changes can be read-
ily observed by light microscopy as major reduction in cellular 
processes, consistent with fi  lopodia and lamellipodia. However, 
cisplatin did not display major cytotoxic effects on MCF-7 cells 
even when kept for 12 h (unpublished data). Because the actin 
cytoskeleton has a major role in formation of cellular processes, 
the effects of cisplatin on the actin network were evaluated 
next. Using phalloidin, which specifi  cally stains F-actin, re-
modeling of actin network was observed after cisplatin treat-
ment. As shown in   Fig. 1 B  , cisplatin disrupted the fi  lamentous 
pattern of phalloidin staining and caused the appearance of 
cortical stress fi  bers. Importantly, phalloidin staining of adher-
ent membranes revealed a decreased membrane-bound F-actin 
after treatment with cisplatin (Fig. S1, available at http://www
.jcb.org/cgi/content/full/jcb.200705060/DC1). Intriguingly, cis-
platin treatment did not alter fi  lamentous (F) to globular (G) 
actin ratio (  Fig. 1 C  ). Therefore, these results suggest that cis-
platin destabilizes membrane anchoring of actin fi  laments, lead-
ing to rearrangement of fi  lamentous actin network and overall 
loss of cellular processes. 
  Relocation of ezrin after 
cisplatin treatment 
  Because the actin-binding protein ezrin plays a major role in 
stabilizing the association of actin fi  laments with the plasma 
membrane, the effect of cisplatin treatment on the distribution 337  INACTIVATION OF EZRIN BY STRESS-INDUCED CERAMIDE   •   ZEIDAN ET AL.
cell periphery in response to cisplatin (  Fig. 4 B  ). In particular, 
imaging of unpermeabilized cells not only confi  rmed this trans-
location process, but it also suggested localization of ASMase to 
the outer cell surface. Notably, the exoplasmic leafl  et has been 
previously shown to be a major site of SM enrichment (  Calderon 
and DeVries, 1997  ;   van Helvoort et al., 1997  ). Lysenin, a hemo-
lytic protein from the earthworm   Eisenia foetida ,  functions 
as a high affi  nity SM-binding protein (  Hanada et al., 1998  ). 
As shown in   Fig. 4 A  , a signifi  cant elevation in ASMase activity 
was observed within 15 min and reached up to twofold over 
baseline after 30 min of cisplatin addition. However, neutral 
sphingomyelinase (NSMase) and secretory sphingomyelinase 
activities (S-SMase) were not signifi  cantly changed along this 
time frame of cisplatin treatment. 
  Importantly, confocal microscopy analysis revealed trans-
location of ASMase from its endolysosomal compartment to the 
  Figure 1.       Effects of cisplatin on MCF-7 cellular cytoskeleton.   
(A) MCF-7 cells were grown on 10-cm dishes up to 60% 
conﬂ   uency. Then cells were treated with either cisplatin 
(5   μ  g/ml) or DMSO for 2 h. Cell morphology was ex-
amined under an inverted light microscope equipped 
with a CCD camera using 20x objectives. Representa-
tive areas are enlarged in the insets. (B) Cells treated as 
in A were ﬁ  xed and stained with rhodamine-phalloidin. 
(C) Cells treated with vehicle (DMSO), phalloidin, cyto-
chalasin D, or cisplatin (60 and 120 min) were analyzed for 
ﬁ  lamentous (F) and globular (G) actin by Western blotting. 
Results were quantitated by densitometry using NIH 
ImageJ. Figures are representative of at least three inde-
pendent experiments.     JCB • VOLUME 181 • NUMBER 2 • 2008  338 
membrane distribution under these experimental conditions. 
Moreover, cisplatin induced signifi  cant colocalization of ASMase 
with lysenin; however, it was noted that ASMase did not 
show a uniform staining in contrast to lysenin (  Fig. 4 C  , inset). 
Therefore, inactivated lysenin was used to evaluate the effects 
of cisplatin on sphingomyelin. A clear drop in fl  uorescence 
intensity of lysenin staining was seen after cisplatin treatment 
(  Fig. 4 C  ); however, lysenin staining retained a uniform plasma 
  Figure 2.       Treatment with cisplatin causes relocation of ezrin.   MCF-7 cells were treated with DMSO or cisplatin (5   μ  g/ml) for 2 h. (A) Cells were ﬁ  xed and 
stained with ezrin-speciﬁ  c polyclonal antibody (green channel) before laser-scanning confocal microscopy. Nuclei were visualized using DRAQ5 nuclear 
dye (red channel). Shown are representative images of multiple experiments. Representative areas are enlarged in the insets. (B) Cells were homogenized 
and fractionated into cytosolic and membrane fractions by centrifugation at 100,000   g  . Amount of ezrin in total, cytosolic, and membrane fractions (con-
centrated eightfold) was detected by Western blotting. (C) MCF-7 cells (5 x 10 
5   cells/10-cm plate) were treated with DMSO or cisplatin (5   μ  g/ml) for the 
indicated time points up to 2 h. Levels of p-ezrin and total ezrin were detected by speciﬁ  c rabbit polyclonal antibodies. (D) Cells treated with DMSO or 
cisplatin (5   μ  g/ml) for 2 h were stained for p-ezrin (green channel) and phalloidin (red channel). Blots from three independent experiments were quantitated 
using NIH ImageJ (*, P   <   0.05). Images are representative of three independent experiments. Bars, 20   μ  m.     339  INACTIVATION OF EZRIN BY STRESS-INDUCED CERAMIDE   •   ZEIDAN ET AL.
next evaluated whether ceramide is suffi  cient for these changes. 
C  16  -ceramide was chosen for these experiments, as it was abun-
dant in MCF-7 cells and almost doubled in response to cisplatin 
(  Fig. 3 C  ). Microscopically, treatment with C  16 -ceramide  re-
capitulated the effects of cisplatin, including loss of fi  lopodia and 
redistribution of ezrin to the cytosol (  Fig. 6 A  ). After separation 
of cytosolic and membrane pools by cell fractionation, Western 
blot analysis revealed reduction of membrane-associated ezrin 
after ceramide treatment (  Fig. 6 B  ). In line with these results, 
treatment of HL-60 cells with short chain C  2  -ceramide was ear-
lier reported to decrease the levels of ERM proteins in the mem-
brane fraction (  Kondo et al., 1997  ), suggesting that the above 
fi  ndings are neither specifi  c to a particular cell line nor a cer-
amide species. Additionally, similar to cisplatin, administration 
of exogenous C  16  -ceramide caused a time-dependent dephosphor-
ylation of ezrin, although dephosphorylation occurred in a more 
acute manner (30 min) (  Fig. 6 C  ). Of note, treatment with the 
ceramide analogue, dihydro-C  16  -ceramide, failed to infl  uence 
the levels of p-ezrin, suggesting a ceramide-specifi  c response. 
Thus, ceramide is not only necessary but also suffi  cient for stress-
induced cytoskeletal responses. 
  The above hypothesis was further evaluated by studying 
the effects of ceramide, endogenously generated through the 
action of bacterial sphingomyelinase (bSMase). Importantly, 
addition of bSMase (100 mU/ml) induced a time-dependent 
dephosphorylation of ezrin (  Fig. 6 D  ), and subcellular redistri-
bution of ezrin from cell periphery to the cytosol was observed 
within 60 min of bSMase addition (  Fig. 6 E  ). This was ac-
companied by a parallel loss of p-ezrin staining from cellular 
fi  lopodia (  Fig. 6 F  ). Collectively, these data suggest that ceramide 
is a key lipid regulator of ezrin function and distribution. 
  PP2A mediates ezrin dephosphorylation 
  Ceramide-activated protein phosphatases (CAPPs) are well 
established effectors of ceramide generating pathways of which 
PP2A and PP1 remain the best studied thus far (  Ruvolo, 2003  ). 
Collectively, these results provide biochemical and cell biological 
evidence that cisplatin modulates the sphingolipid pathway through 
activating ASMase. 
  ASMase is upstream of ezrin 
dephosphorylation and the 
cytoskeletal changes 
  Given the above results, it became important to investigate 
whether changes in sphingolipid metabolites mediate the action 
of cisplatin. Therefore, knockdown of ASMase was attempted us-
ing RNAi technology. Two different 21-bp oligonucleotides tar-
geting ASMase or a control (scrambled) sequence were transfected 
into MCF-7 cells. Western blotting confi  rmed loss of the ASMase 
protein (  >  70%) after 48 h of RNAi transfection (  Fig. 5 A  ). Impor-
tantly, knockdown of ASMase blocked cisplatin-induced ezrin 
dephosphorylation as determined by Western blotting (  Fig. 5 B  ). 
  This result prompted us to defi  ne the role of ASMase in 
cisplatin-induced cytoskeletal changes. To this end, cells were 
transfected with either ASMase RNAi or SCR oligonucleotides 
for 48 h. Confocal microscopy imaging revealed that cisplatin 
treatment caused an overall rounding, loss of cellular fi  lopodia, 
and relocation of ezrin to a more cytosolic distribution in the 
control group (SCR). It is worth noting that a normal nuclear 
morphology was maintained (red channel), suggesting that the 
observed changes are not secondary to cell death. Importantly, 
cells transfected with ASMase RNAi were remarkably protected 
from the morphological effects of cisplatin. This was indicated 
by retention of not only cellular fi  lopodia but also peripheral 
ezrin localization after cisplatin treatment (  Fig. 5 C  ). Therefore, 
these fi  ndings suggest a critical role for ASMase in mediating 
the cytoskeletal effects of cisplatin. 
  Exogenous ceramide recapitulates the 
cytoskeletal effects induced by cisplatin 
  Because the above results suggested that ceramide production 
is necessary for cytoskeletal changes induced by cisplatin, we 
  Figure 3.       LC/MS analysis of cisplatin effects 
on ceramide and sphingomyelin.   Cells were 
treated with cisplatin (5   μ  g/ml) for 15, 30, 
60, or 180 min. After Bligh Dyer extraction of 
lipids, the different treatment groups were sub-
jected to mass spectrometric analysis as indi-
cated in Materials and methods. Sphingolipids 
measurements were normalized to total phospho-
lipids. Shown are the normalized results for (A) 
total ceramide, (B) total SM, (C) C  16   and C  24:1  -
ceramide, and (D) C  16   and C  24:1  -SM. Ceramide 
and SM results represent averages   ±   S.E. from 
three independent experiments.     JCB • VOLUME 181 • NUMBER 2 • 2008  340 
(SCR) or PP2A-specifi  c 21-bp oligonucleotides. After 48 h, 
marked knockdown (  >  70%) of PP2A protein was observed by 
Western blotting (  Fig. 7 C  ). Importantly, loss of PP2A con-
ferred protection from cisplatin-induced ezrin dephosphorylation 
( Fig.  7  C ).  These  fi  ndings provide strong pharmacologic and 
genetic evidence for PP2A in ezrin dephosphorylation. 
  Because p-ezrin localizes primarily at (or close to) the 
plasma membrane, it became important to determine the effects 
of cisplatin on PP2A localization and possible association of 
PP2A and ezrin. For these studies, a FRET microscopy ap-
proach was used whereby CFP-PP2A served as the donor and 
YFP-ezrin as the acceptor. As shown in   Fig. 7 D  , within 30 min, 
cisplatin treatment induced redistribution of PP2A from the 
cytosol to the cell periphery. Importantly, this redistribution of 
Therefore, it became important to determine whether the observed 
dephosphorylation of ezrin is mediated by CAPPs. In previous 
studies, it was demonstrated that okadaic acid potently inhibits 
PP2A when used at low doses (  Chalfant et al., 1999, 2001  ). 
Cells were pretreated with either okadaic acid (10 nM) or vehi-
cle (DMSO) 1 h before cisplatin addition. Western blot analysis 
revealed that inhibition of PP2A with okadaic acid restored 
levels of p-ezrin (  Fig. 7 A  ). We also entertained the potential 
involvement of another well-established ceramide activated 
phosphatase, PP1. However, treatment with tautomycin (10 nM), 
a specifi  c PP1 inhibitor, had little effect on cisplatin-induced 
ezrin dephosphorylation (  Fig. 7 B  ). These results were further 
corroborated using RNAi technology. For these experiments, 
MCF-7 cells were transfected with 20 nM of either control 
  Figure 4.       Activation of ASMase after treatment 
with cisplatin.   (A) MCF-7 cells were treated with 
either DMSO or cisplatin (5   μ  g/ml) for 15, 30, 
60, or 180 min. Total lysates (100   μ  g/sample) 
were subjected to SMase assays (ASMase, 
NSMase; neutral sphingomyelinase and S-SMase; 
secretory sphingomyelinase) as described under 
Materials and methods. Results shown are 
averaged from three enzymatic assays   ±   S.E. 
(*, P   <   0.05). (B and C) Cells plated on 2-cm 
confocal dishes (5 x 10 
5   cells/plate) were 
transfected with 1   μ  g of the V5-ASMase plasmid. 
After 24 h, cells were incubated with either 
DMSO or cisplatin (5   μ  g/ml) for 30 min. Local-
ization of ASMase was detected using a V5 
monoclonal antibody (green channel) in per-
meabilized (B) or non-permeabilized cells (C). 
Sphingomyelin was visualized indirectly using 
the SM-binding protein, lysenin (red channel). 
Immunoﬂ   uorescence was performed using a 
polyclonal lysenin antibody. Nuclei (NUC) were 
labeled using DRAQ5 nuclear dye. Shown are 
representative images of three independent 
experiments. Bars, 5   μ  m.     341  INACTIVATION OF EZRIN BY STRESS-INDUCED CERAMIDE   •   ZEIDAN ET AL.
platin, the role of PKC     in this process was evaluated. Therefore, 
cells were infected with either control adenoviruses (LacZ) 
or viruses encoding a dominant-negative construct of PKC    
(DN-PKC    ) before stimulation with cisplatin. In comparison 
with the control group, cells infected with DN-PKC     showed  a 
signifi  cant reduction in ASMase activity after cisplatin treatment 
(  Fig. 8 B  ). Additionally, the effect of DN-PKC     on cisplatin-
induced ASMase relocation was evaluated. The results revealed 
a 40% drop (65% inhibition of the response) in cells showing 
plasma membrane translocation of ASMase after cisplatin treat-
ment (  Fig. 8 C  ). 
  Moreover, because we had identifi  ed phosphorylation of 
S508 residue in ASMase as an essential step for ASMase trans-
location, we next studied the role of this residue in cisplatin-
induced ASMase translocation. To this end, cells overexpressing 
V5-tagged WT-ASMase or ASMase 
S508A   were treated with cis-
platin for 30 min. As shown in   Fig. 8 D  , although ASMase 
PP2A increased FRET effi  ciency to 40%, suggesting that PP2A 
was in close proximity to ezrin (nm). Intracellular relocation of 
overexpressed YFP-ezrin was observed after 60 min of cisplatin 
treatment along with a drop of FRET effi  ciency to baseline 
level. Together, these results suggest that PP2A mediates ezrin 
dephosphorylation during stress-induced ceramide. 
  PKC     mediates activation of ASMase 
by cisplatin 
 Recently,  we  defi  ned a mechanism for ASMase activation in 
which PKC     serves as a key upstream kinase (  Zeidan and Hannun, 
2007  ). Therefore, we investigated whether cisplatin treatment 
modulated PKC activity in MCF-7 cells. In vitro kinase assays 
revealed a signifi  cant elevation (1.5-fold) in PKC     activity  by 
30 min and further elevation (3-fold) after 1 h of cisplatin treat-
ment (  Fig. 8 A  ). Because this time frame of PKC     induction 
is consistent with the kinetics of ASMase activation by cis-
  Figure 5.       ASMase is upstream of cisplatin-
induced ezrin dephosphorylation.   (A) MCF-7 
cells were transfected with 10 nM of either 
SCR or ASMase RNAi oligonucleotides. After 
48 h, levels of ASMase and     -actin were de-
termined by Western blotting and quantitated 
by densitometry. (B) Cells were treated with ei-
ther DMSO or cisplatin (5   μ  g/ml) for 60 min. 
Lysates (30   μ  g) from each treatment group 
were used to detect levels of phosphorylated 
ezrin (p-ezrin) and ezrin by Western blotting. 
Blots from three independent experiments were 
quantitated using NIH ImageJ (**, P   <   0.01; 
n.s, non signiﬁ  cant). (C) Cells plated on 2-cm 
confocal dishes were transfected with 20 nM 
of SCR or two ASMase RNAi oligonucleotides 
(ASMase RNAi [1] and [2]). After 48 h, cells 
were treated with either DMSO or cisplatin for 
60 min. Then cells were ﬁ  xed and stained us-
ing ezrin-speciﬁ  c polyclonal antibody. Images 
are representative of three independent experi-
ments. Bars, 10   μ  m.     JCB • VOLUME 181 • NUMBER 2 • 2008  342 
hypothesized that inactivation of ezrin by cisplatin treatment 
infl  uences cellular motility. This hypothesis was tested using a 
wound-healing assay applied to confl  uent monolayers of MCF-7 
cells stably overexpressing WT ASMase or ASMase 
S508A . As shown 
in  Fig. 9 A , under basal conditions both ASMase and ASMase 
S508A  
stables were able to reduce the wound to 27% of its original size 
after 48 h. Importantly, the wound-healing ability of cells incu-
bated with cisplatin (5   μ  g/ml) was markedly reduced to only 70% 
of original wound size, indicating reduced migration in the presence 
of cisplatin. On the contrary, cells overexpressing ASMase 
S508A  
were signifi  cantly refractory to the effects of cisplatin, as they were 
translocation could be detected in 75   ±   10% of WT-ASMase cells, 
this response could be seen in only 22   ±   9% of ASMase 
S508A  
cells. Collectively, these results strongly suggest that activation 
of ASMase by cisplatin is mediated by PKC   . 
  ASMase mediates the effect of cisplatin 
on cell migration 
  Recent studies have indicated a major role for ezrin in regulating 
cellular motility (  Fievet et al., 2007  ;   Prag et al., 2007  ). In partic-
ular, the active phosphorylated form of ezrin is tumor promoting 
as it enhances cellular migration and invasion. Therefore, we 
  Figure 6.       Exogenous ceramide mimics cyto-
skeletal effects of cisplatin.   MCF-7 cells were 
treated with D-e-C  16  -ceramide (5   μ  M) or ve-
hicle (2% dodecane/98% ethanol) for 2 h. 
(A) Cells were ﬁ   xed and stained with ezrin-
speciﬁ  c polyclonal antibody (green channel). 
Nuclei were visualized using DRAQ5 nuclear 
dye. (B) Cells were homogenized and fraction-
ated into a cytosolic and membrane fractions 
by centrifugation at 100,000   g  . Amount of 
ezrin in total, cytosolic, and membrane frac-
tions (concentrated eightfold) was detected by 
Western blotting. (C) Cells were treated with 
D-e-C  16  -ceramide (5  μ  M), dh-C 16  -ceramide (5  μ  M), 
or vehicle (2% dodecane/98% ethanol) up to 
3 h. Levels of p-ezrin and total ezrin were de-
tected by Western blotting. (D) Cells treated 
with bSMase (100 mU/ml) for 0, 15, 30, and 
60 min were subjected to Western blot analy-
sis for ezrin and p-ezrin levels. (E) Subcellular 
distribution of ezrin in control cells and cells 
treated with bSMase (100 mU/ml) for 60 min. 
(F) Cells treated as in D were stained for p-ezrin 
(green channel) and phalloidin (red channel). 
Results are representative of three independent 
experiments. Blots from three independent ex-
periments were quantitated using NIH ImageJ 
(*, P   <   0.05). Bars, 20   μ  m.     343  INACTIVATION OF EZRIN BY STRESS-INDUCED CERAMIDE   •   ZEIDAN ET AL.
ezrin T567D or a control plasmid. The results showed that cells 
expressing ezrin T567D were resistant to cisplatin as they rescued 
the wound size to 40% of its original size within 48 h (  Fig. 9 B  ). 
In contrast, cells transfected with the control plasmid retained 
75% of the wound size, suggesting impaired migration in pres-
ence of cisplatin (  Fig. 9 B  ). Therefore, regulation of ezrin appears 
to be critical for the effect of cisplatin on cellular migration. 
  Discussion 
  The results in this study demonstrate that the ASMase/ceramide 
pathway is instrumental for remodeling of cellular architecture 
still able to reduce wound size to 40%. Importantly, ASMase 
S508A  
cells were also refractory to ezrin dephosphorylation and cyto-
solic translocation after cisplatin treatment as compared with 
WT-ASMase cells (Fig. S2, A and B; available at http://www.jcb
.org/cgi/content/full/jcb.200705060/DC1). Together, these fi  nd-
ings strongly suggest that suppression of cellular motility by 
cisplatin requires activation of ASMase. 
  Previous studies have shown that the T567D mutant form 
of ezrin mimics structural and functional properties of phosphor-
ylated ezrin (  Gautreau et al., 2000  ;   Bretscher et al., 2002  ). To in-
vestigate the role of ezrin in the cisplatin response discussed 
above, we studied the migratory response of cells expressing 
  Figure 7.       PP2A mediates dephosphorylation of 
ezrin by cisplatin.   Cells plated on 10-cm dishes (5   ×   
10 
5   cells/dish) were pretreated with 10 nM of either 
okadaic acid (A) or tautomycin (B). After 1 h, cells 
were incubated with DMSO or cisplatin (5   μ  g/ml) for 
1 h. Phospho-ezrin levels were evaluated by Western 
blotting using a speciﬁ  c polyclonal antibody. (C) Cells 
were transfected with 20 nM of either SCR or PP2A 
(catalytic subunit) speciﬁ  c oligonucleotides. After 48 h, 
cells were subjected to DMSO or cisplatin treatments 
for 1 h. Lysates (30   μ  g) were analyzed by Western 
blotting for levels of p-ezrin and PP2A. Blots shown 
are representative of at least three independent exper-
iments. Densitometric analysis was performed using 
NIH Image software. (D) MCF-7 cells expressing YFP-
ezrin and CFP-PP2A (catalytic subunit) were subjected 
to sensitized emission FRET analysis. After 24 h of 
plasmid transfection, cells were treated with DMSO 
or cisplatin for 30 and 60 min. A representative FRET 
image of at least 30 cells imaged in three experiments 
is shown. FRET efﬁ  ciencies are encoded by using the 
color bar scale shown on the left. Colors range be-
tween blue (lowest FRET) and red (highest FRET).     JCB • VOLUME 181 • NUMBER 2 • 2008  344 
volving ASMase/ceramide in mediating stress responses on the 
actin cytoskeleton. 
  A major conclusion from this study emanates from defi  ning 
a novel molecular/biochemical mechanism for ezrin inactivation. 
Previous studies demonstrated that binding of the phosphoinos-
itide PIP2 at the N terminus of ezrin facilitates its conformational 
change (  Fievet et al., 2004  ). However, reciprocal regulation (in-
activation) of ezrin by other bioactive lipids and by other path-
ways remains largely unknown. The data presented here suggest 
that the ASMase/ceramide pathway mediates stress-induced 
ezrin dephosphorylation and consequent retraction of fi  lopodia 
(  Fig. 10  , model). This model is supported by several lines of 
evidence. First, cisplatin activated ASMase and induced ceramide 
in a time course consistent with a role upstream of ezrin de-
phosphorylation. Second, genetic knockdown of ASMase blocked 
ezrin dephosphory  lation and restored cellular morphology after 
during stress responses. Treatment with cisplatin caused loss of 
fi  lopodia and rearrangement of the actin cytoskeleton. These 
morphological changes were associated with dephosphorylation 
of ezrin and its further relocation from the plasma membrane to 
the cytosol. Knockdown of ASMase rescued cells from cisplatin-
induced ezrin inactivation and overall morphological change, 
demonstrating a critical role for ASMase. Moreover, addition of 
C  16  -ceramide recapitulated the effects of cisplatin on ezrin and 
on the cytoskeleton, indicating that activation of the ASMase/
ceramide pathway is suffi  cient for induction of these responses. 
Mechanistically, the results demonstrate a critical role for PKC    
upstream of ASMase and for PP2A downstream of ceramide in 
the dephosphorylation of ezrin. Functionally, dephosphorylation/
inactivation of ezrin correlated with reduced mobility of 
MCF-7 cells after cisplatin treatment in an ASMase-dependent 
manner. Collectively, these results identify a novel pathway in-
  Figure 8.       PKC     is upstream of ASMase activation by cis-
platin.   (A) MCF-7 cells (5   ×   10 
5   cells/plate) were treated 
with DMSO or cisplatin (5   μ  g/ml) for 5, 30, 60, or 180 min. 
PKC     was immunoprecipitated from lysates of each 
treatment group and subjected to in vitro kinase assay as 
described in Materials and methods  .    
32  P-MBP was visual-
ized by autoradiography. Average densitometric analysis + 
S.E. of three independent experiments are plotted. 
(B) Cells were infected with control LacZ or DN-PKC     adeno-
viruses (multiplicity of infection of 50). After 24 h, cells 
were treated with DMSO or cisplatin for 30 min. Samples 
of total lysates (100   μ  g) were then subjected to in vitro 
ASMase assay. (C and D) Cells overexpressing ASMase 
(or ASMase 
S508A  ) were infected with LacZ or DN-PKC     
adenoviruses as in B before treatment with either DMSO 
or cisplatin for 30 min. Localization of ASMase was ob-
served by confocal microscopy using a V5 monoclonal 
antibody staining in permeabilized cells. Percentage of 
cells showing plasma membrane translocation of ASMase 
was quantitated from at least 10 random visual ﬁ  elds 
each containing 15  –  20 cells per ﬁ  eld. (*, P   <   0.05). ns, 
not signiﬁ  cant.     345  INACTIVATION OF EZRIN BY STRESS-INDUCED CERAMIDE   •   ZEIDAN ET AL.
  Figure 9.       Differential migratory response of WT-ASMase vs. ASMase 
S508A       cells to cisplatin treatment.   MCF-7 cells stably overexpressing WT-ASMase or 
ASMase 
S508A   were treated with either cisplatin or DMSO. (A) Cell migration was analyzed by wound-healing assay as described under Materials and 
methods  .   Wound size was measured at 0, 24, and 48 h after scratching a conﬂ  uent monolayer of cells. (B) Cells overexpressing ezrin T567D or a control 
(pCB6) plasmid were subjected to the wound-healing migration assay. Cell migration was assessed by measuring wound size at 0, 24, and 48 h. Results 
shown are representative of three independent experiments (*, P   <   0.05).     JCB • VOLUME 181 • NUMBER 2 • 2008  346 
1997  ]), histone deacetylase inhibitors (  Rahmani et al., 2005  ), 
fenretinide (  Lovat et al., 2004  ), and microtubule-targeting agents 
(paclitaxel [  Prinetti et al., 2006  ]). Activation of ASMase by these 
agents has been associated with apoptotic cell death. Although 
the actions of chemotherapies are not limited to cell killing, the 
role of ASMase in responses other than cytotoxicity have not 
been well studied. For the fi  rst time, the results presented in this 
study demonstrate that ASMase hinders the mobility of mamma-
lian cells through remodeling of the cellular cytoskeleton. 
  The present study established that ceramide signaling 
mediates the cytoskeletal rearrangement produced by cisplatin. 
Recently, identifi  cation of the morphotropic properties of ceramide 
and other bioactive sphingolipids has emerged as an important 
goal. Sphingosine-1-phosphate (S1P), a catabolite of ceramide, 
elicits profound cytoskeletal effects mainly through regulating 
Rho GTPases (  Toman et al., 2004  ;   Donati and Bruni, 2006  ). 
Although an increase in ceramide and a drop in S1P may be det-
rimental for cell survival ( Maceyka et al., 2002 ), the current study 
suggests that the bioactive lipid ceramide also governs cellular 
morphology and its associated biological processes. For the fi  rst 
time, we show that ceramide modulates the actin cytoskeleton by 
inducing dephosphorylation of ezrin. These changes seem to be 
specifi  c to ceramide, as the inactive dihydroceramide analogue 
failed to dephosphorylate ezrin. Using the same cell line used in 
this study, Panigone et al. (  2001  ) observed that up-regulation of 
prosaposin, an activator of ASMase, or treatment with C  2 -ceramide, 
causes defective cell spreading and impaired adhesion. Such 
cytoskeletal responses elicited by ceramide do not seem to be 
specifi  c for MCF-7 cells, as similar observations have been made 
cisplatin treatment. Third, cells overexpressing DN ASMase 
S508A  
maintained levels of p-ezrin after cisplatin treatment and, more 
importantly, preserved their migratory response in a wound-
healing model. Finally, addition of exogenous ceramide mimicked 
the morphotropic effects of cisplatin including dephosphorylation 
of ezrin. 
 These  fi  ndings hold major biological implications to tumor 
progression and therapy. Mounting evidence indicates a role for 
ezrin not only in tumor survival but also in tumor migration and 
invasion (  Curto and McClatchey, 2004  ). Aberrant overexpres-
sion of ezrin has been documented in a myriad of cancers, some 
of which hold fatal clinical prognosis such as pancreatic tumors. 
Additionally, ezrin has been linked to regulation of P-glycoprotein, 
a pump that is involved in multiple drug resistance (  Luciani 
et al., 2002  ). As such, ezrin has emerged as a candidate target for 
cancer therapy. Based on the current study, one could speculate 
that cisplatin and/or ceramide analogues could be used to com-
bat tumors of high ezrin levels. Intriguingly, using in vivo mouse 
models,   Stover et al. (2005  ) showed that intravenous delivery 
of liposomal ceramide reduced the dissemination of ovarian and 
breast cancers. However, the underlying mechanisms were not 
investigated (  Stover et al., 2005  ). 
  The results from this study also signifi  cantly extend the 
spectrum of stress responses mediated by ceramide. Modulation 
of sphingolipid metabolism is emerging as a shared cellular stress 
response to chemotherapy (  Bezombes et al., 2003  ;   Marchesini 
and Hannun, 2004  ). In particular, the ASMase/ceramide pathway 
has been suggested as a target for different classes of cytotoxic 
drugs including: DNA damaging agents (doxorubicin [  Herr et al., 
  Figure 10.       Model of cisplatin-induced cytoskeletal remodeling.   The model depicts activation of the ASMase/ceramide pathway by cisplatin as a key step 
upstream of actin rearrangement. The serine/threonine phosphatase PP2A links ceramide generation to ezrin dephosphorylation and cytosolic relocation. 
Inactivation of ezrin results in dissociation of actin ﬁ  laments from the plasma membrane and resorption of cellular ﬁ  lopodia.     347  INACTIVATION OF EZRIN BY STRESS-INDUCED CERAMIDE   •   ZEIDAN ET AL.
that cisplatin targets lysosomal proteases such as cathepsin D 
(  Emert-Sedlak et al., 2005  ). Interestingly, cathepsin D has been 
previously shown as a downstream protease of ASMase activa-
tion and a key ceramide-binding protein (  Heinrich et al., 1999, 
2000, 2004  ). Although we did not directly address whether acti-
vation of ASMase by cisplatin is mediated by a nuclear signal, 
a recent study by Charruyer et al. (  2005  ) demonstrating activa-
tion of ASMase in platelets after UV radiation supports a model 
of ASMase that is independent of nuclear signaling. Of note, 
other reports have shown intact cytotoxic effects of cisplatin in 
enucleated cells (cytoplasts) (  Mandic et al., 2003  ). 
  In conclusion, the results in this study demonstrate that the 
ASMase/ceramide pathway conveys stress signals to the actin 
cytoskeleton machinery. The study unveils a novel sphingolipid-
mediated mechanism of ezrin regulation. Based on these fi  ndings, 
a hypothetical model of stress-induced cytoskeletal remodeling 
is illustrated in   Fig. 10  . 
  Materials and methods 
  Materials 
  Cell culture material including RPMI media, fetal bovine serum (FBS), and 
the antibiotic blasticidin S were from Invitrogen. Bovine sphingomyelin and 
phosphatidylserine were from Avanti Polar Lipids, Inc. [  Choline  -  methyl  - 
14  C] 
sphingomyelin, C  16  -ceramide, and dhC  16  -ceramide were provided by 
Dr. Alicja Bielawska (The Lipidomics Core at the Medical University of South 
Carolina, Charleston, SC). Antibodies against PKC     (polyclonal) and HRP-
conjugated secondary antibodies were from Santa Cruz Biotechnology, 
Inc. Monoclonal antibodies against the V5 epitope were from Invitrogen. 
PP2A (catalytic subunit     ) antibody was from BD Biosciences. ASMase 
polyclonal antibody has been previously described (  Zeidan and Hannun, 
2007  ). Polyclonal ezrin antibody (antibody 1; Millipore) was used for 
Western blotting. A second ezrin polyclonal antibody (antibody 2; Cell 
Signaling Technology) was used for immunoﬂ  uorescence. Anti p-ERM anti-
body and the second anti-ezrin antibody were purchased from Cell Signal-
ing Technology. AlexaFluor 488, 633, and 546 were from Invitrogen. 
Okadaic acid and tautomycin were purchased from Calbiochem. Lysenin, 
cisplatin, bacterial sphingomyelinase derived from   Bacillus cereus  , and all 
other materials were from Sigma-Aldrich. 
  Cell lines and culture conditions 
  MCF-7 cells were originally purchased from American Type Culture Collec-
tion (Manassas, VA). Cells were maintained in RPMI 1640 supplemented 
with 10% FBS at 37  °  C in a 5% CO  2   incubator. Where indicated, cells 
were shifted to a phosphate-free medium. Testing for the presence of myco-
plasma infections was performed routinely on a monthly basis. 
  Immunoprecipitation and Western blotting 
  Cells were treated as indicated in ﬁ  gure legends. Cells were then lysed in 
a buffer containing 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1% NP-40, 
2 mM EDTA, 5 mM sodium ﬂ  uoride, 1.75 mM sodium orthovanadate, 1 mM 
phenylmethylsulfonyl ﬂ  uoride, 20 mM     -glycerol phosphate, 10   μ  g/ml 
leupeptin, 10   μ  g/ml aprotinin, and 1   μ  M microcystin. Homogenates were 
centrifuged at 3,000   g   for 10 min. The supernatants were used for immuno-
precipitation using speciﬁ  c monoclonal antibodies (1   μ  g/ml) overnight. 
Immune complexes were isolated by incubation with protein G  –  Agarose 
beads for 3 h. Western blot analysis was carried using similar procedures 
as described previously (  Zeidan et al., 2006  ). 
  SMase assays 
  In vitro enzymatic assays for acid and neutral sphingomyelinases were per-
formed using [  choline  -  methyl  - 
14  C] sphingomyelin. The assays were performed 
as previously reported (  Marchesini et al., 2003  ;   Zeidan et al., 2006  ). 
  RNA interference 
  Gene silencing of human ASMase and PP2A (catalytic subunit) was 
performed essentially according to a standard protocol (  Zeidan et al., 
2006  ). Sequence-speciﬁ  c ASMase siRNA reagents were purchased from 
QIAGEN. The sequences of ASMase RNAi duplexes were sequence [1]: 
by other investigators in different cell lines. In a recent study, 
Hu et al. (  2005  ) demonstrated that exogenous C  6 -ceramide 
  induced loss of fi  lopodia in HeLa cells. The divergence of the 
morphological effects of ceramide from apoptosis was demon-
strated by Spinedi and coworkers, as caspase inhibitors blocked 
only cell death but not detachment (  Di Bartolomeo and Spinedi, 
2002  ). With this in mind, one can propose that ceramide derives its 
tumor suppressor properties from being not only a pro-apoptotic 
lipid, but also a morphotropic one. 
  The results from this study also signifi  cantly extend our 
understanding of signaling mechanisms both upstream and 
downstream of ASMase. Upstream, the results implicate PKC    
in this pathway. Although activation of ASMase was reported 
to be a critical step for cisplatin-induced ceramide generation 
(  Lacour et al., 2004  ), the molecular mechanism underlying this 
process is not known. A critical role for PKC     in mediating ac-
tivation of ASMase by cisplatin is supported by several lines of 
evidence. In vitro enzymatic assays revealed similar kinetics for 
ASMase and PKC     activation after cisplatin treatment. Addi-
tionally, infection with DN-PKC     adenovirus impaired not only 
activation but also membrane translocation of ASMase in re-
sponse to cisplatin. These results are in concert with our re-
cently reported mechanism of ASMase regulation (  Zeidan and 
Hannun, 2007 ) in which activation of ASMase proceeds through 
PKC    -mediated phosphorylation of the enzyme at S508. The va-
lidity of this model is further corroborated by the fi  nding that the 
ASMase 
S508A   mutant failed to translocate to the plasma mem-
brane after cisplatin treatment. 
  As to downstream mechanisms, the identifi  cation of ezrin 
as a target for PP2A-mediated dephosphorylation extends the 
current understanding of PP2A as a regulator of cellular motil-
ity. Previous work from our laboratory and others established 
PP2A as a lipid-binding phosphatase that is activated upon 
ceramide binding to its catalytic domain (  Chalfant et al., 1999, 
2004  ). Although the catalytic activity of PP2A has been tightly 
associated with reduced cellular motility in various tumors, 
there is little molecular understanding of this process. The pre-
sent study proposes regulation of ezrin as a key mechanism by 
which PP2A limits cellular motility. First, targeting PP2A using 
pharmacologic (okadaic acid) and genetic approaches (RNAi) 
blocked ezrin dephosphorylation. Second, FRET experiments 
uncovered an association of PP2A and ezrin at the cell mem-
brane in response to cisplatin. Furthermore, dephosphorylation 
of ezrin at Thr 526 seemed to be specifi  cally carried by PP2A 
but not PP1, another ceramide-activated phosphatase, as inhibi-
tion of PP1 with tautomycin did not rescue levels of p-ezrin. 
It is worth noting that dephosphorylation of ERM proteins has 
been previously reported in response to chemokines such as SDF 
(  Brown et al., 2003  ), FMLP, and GM-CSF (  Yoshinaga-Ohara 
et al., 2002  ), but the identities of the phosphatases involved 
were not established. 
  Based on the current fi  ndings, ASMase emerges as a novel 
extranuclear target for cisplatin action. Although classically 
  regarded as a nuclear DNA damaging agent, recent studies 
  support a more promiscuous mode of cisplatin action.   Safaei 
et al. (2005)   demonstrated that fl  uorescently labeled cisplatin 
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lysate fractions (T). The membrane fraction (Mb) was obtained by centrifu-
gation at 100,000   g   at 4  °  C for 1 h. The resultant supernatant was denoted 
as the cytosolic fraction (C). 
  Mass spectroscopy for ceramide and sphingomyelin 
  Sphingolipid analysis was performed using Electrospray Ionization/
Tandem Mass Spectrometry (ESI-MS/MS) on a Thermo Finnigan TSQ 
7000 triple quadrupole mass spectrometer, operating in a multiple re  action 
monitoring positive ionization mode. This method has been recently described 
(  Bielawski et al., 2006  ). 
  Cell wounding and migration assay 
  5 x 10 
5   MCF-7 cells stably transfected with V5-ASMase or V5-ASMase 
S508A   
were plated in 6-well culture plates in RPMI medium plus 10% FBS. When 
cultures were 80% conﬂ  uent, wounding was performed with a 200-  μ  l 
Eppendorf micropipette tip. Cells were then washed twice with PBS followed 
by addition of fresh medium supplemented with mitomycin C (0.5   μ  g/ml) 
to control for proliferation. Immediately after wounding, cells were in-
spected under the microscope (Eclipse TE 200; Nikon) (t = 0). Then at 24 
and 48 h, cell migration was analyzed by measuring the maximum migra-
tion distance of the cell front into the wounded area. Experiments were 
performed in triplicate and the distance was measured in three ﬁ  elds of 
each well. 
  Preparation of adherent plasma membranes 
  MCF-7 cells were grown on poly-  L  -lysine coated confocal dishes 2 cm in 
diameter. Using a syringe with 25-gauge needle, cells were subjected to re-
peated streams of 5 ml buffer A: pH 7.4, 10 mM Hepes, 50 mM KCl, and 
2 mM MgCl  2  . Membranes were checked by light microscopy, ﬁ  xed with 
4% formaldehyde, and stained with rhodamine-phalloidin. 
  F-actin/G-actin in vivo assay 
  The ratio of ﬁ  lamentous actin (F-actin) to globular actin (G-actin) in MCF7 
cells was analyzed using an F-actin/G-actin in vivo assay kit (Cytoskeleton, 
Inc.) based on the manufacturer  ’  s protocol. In brief, following indicated 
treatments cells were lysed with a cell lysis/F-actin stabilization buffer con-
taining 1 mM ATP and protease inhibitor cocktail. Cells were homogenized 
by 10 passages through a 28.5-gauge insulin syringe and incubated for 
10 min at 37  °  C. Positive control lysates were incubated with 1   μ  M phalloi-
din, and negative control lysates were incubated with 10   μ  M cytochalasin D. 
The cell lysates were cleared of unbroken cells and cellular debris by 5 min 
centrifugation at 2,000 rpm (37  °  C) followed by centrifugation of the 
supernatant at 100,000   g   for 60 min (37  °  C) to separate F-actin (pellet) 
from G-actin (supernatant). The supernatants were separated from the pel-
lets and were immediately placed on ice. The pellets were resuspended to 
the same volume as the supernatants using ice cold Milli-Q water contain-
ing 10   μ  M cytochalasin D and were incubated on ice for 60 min. Samples 
were then diluted 10-fold in cold Milli-Q water, and equal volumes (20   μ  l 
per lane) were resolved by SDS-PAGE and analyzed by Western blotting 
with an anti-actin antibody provided with the kit. Western blotting was per-
formed as described above. 
  Statistical analysis 
  Mann-Whitney or student  ’  s   t   tests were performed between control and 
treated states and/or between treatment and treatment plus RNAi-mediated 
inhibition states on a minimum of three independent experiments. A P-value 
of 0.05 or less is considered as statistically signiﬁ  cant and indicated with 
an asterisk. 
  Online supplemental material 
  Fig. S1 demonstrates the effect of cisplatin on membrane-bound F-actin. 
Fig. S2 shows resistance of ASMase 
S508A   cells to cisplatin. Online sup-
plemental material is available at http://www.jcb.org/cgi/content/full/
jcb.200705060/DC1. 
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sense CUC CUU UGG AUG GGC CUG G antisense CCA GGC CCA UCC 
AAA GGA G, and sequence [2]: sense GGU CUA UUC ACC GCC AUC A 
antisense UGA UGG CGG UGA AUA GAC C. The PP2A (catalytic subunit     ) 
RNAi was purchased from Santa Cruz Biotechnology, Inc. The speciﬁ  city of 
all RNAi sequences was veriﬁ  ed by sequence comparison with the human 
genome database using the NIH Blast program. 
  Plasmid constructs and subcloning procedures 
  The V5-ASMase plasmid has been previously described (  Zeidan and 
Hannun, 2007  ). Full-length ezrin cDNA and ezrin T567D were a gift of 
Dr. Monique Arpin (INSERM, Paris, France). The full-length cDNAs of ezrin 
and PP2A     (catalytic subunit) were subcloned into pECFP-C1 and p-EYFP-
N1 plasmids, respectively. The CFP tag is situated at the N terminus of 
PP2A, and the YFP tag is situated at the C terminus of ezrin. EcoRI and 
BamH1 restriction enzymes were used to place the 929-bp PP2A sequence 
in frame. EcoRI and SalI restriction enzymes were used to place human 
ezrin 1760 bp in frame. The integrity of the newly developed plasmids was 
veriﬁ  ed by DNA sequencing. For transient overexpression experiments, 
endotoxin-free plasmids were transfected into MCF-7 cells using Effectene 
(QIAGEN) according to the manufacturer  ’  s recommendations. LacZ and 
DN-PKC     adenoviruses were provided by Dr V. Natarajan (The Johns 
Hopkins University, Baltimore, MD). 
  In vitro PKC     kinase assay 
  PKC     immune complexes were washed four times with ice-cold kinase 
buffer (50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 10 mM MgAc, 0.5 mM 
EGTA, and 0.1 mM DTT). Immunoprecipitates were incubated with the 
assay buffer consisting of 20   μ  M ATP, 5   μ  Ci  
32  P-ATP, 0.2 mg/ml MBP 
in the presence of 0.2 mg/ml phosphatidylserine and 20   μ  g/ml DAG. 
The reaction was carried at 30  °  C for 15 min and terminated by addition 
of SDS-PAGE sample buffer. Proteins were separated by electrophoresis, 
and autoradiography was performed. Samples from each treatment 
group were tested for equal levels of PKC     after immunoprecipitation by 
Western blotting. 
  Confocal microscopy 
  Approximately 5   ×   10 
4   cells were seeded into 2-cm poly-  L  -lysine coated 
confocal plates (MatTek Corp). After treatment, cells were ﬁ  xed with 4% 
paraformaldehyde for 10 min and permeabilized with methanol for 5 min. 
Blocking was performed in 2.5% FBS solution. Primary antibodies were 
diluted in a solution of 1.5% FBS/0.15% saponin and incubated for 3 h 
(1:200 dilution). The samples were then washed with 1.5% FBS solution 
three times. This was followed by incubation with secondary antibodies for 
1 h at room temperature. Samples were stored at 4  °  C until image acquisi-
tion. Images were acquired using a laser-scanning confocal microscope 
(LSM 510; Carl Zeiss, Inc.). Excitation wavelengths 488, 543, and 633 
were used. Images were acquired at the equatorial plane of monolayer 
cells guided by DRAQ5 (Qbiogene) nuclear stain and processed using 
LSM 5 Image Browser (Carl Zeiss, Inc.). 
  Fluorescence resonance energy transfer (FRET) was used to evaluate 
protein  –  protein interaction of PP2A and ezrin in the presence or absence 
of cisplatin. The applied FRET parameters were: excitation for CFP: 458 nm 
(argon laser), emission: BP (band pass) 475  –  525 nm, and excitation 
for YFP: 514 nm (argon laser) emission LP (long pass) 530. MCF-7 cells 
were co-transfected with CFP-PP2A (catalytic subunit     ) and YFP-ezrin using 
standard protocols and incubated for 24 h. Images were acquired using a 
laser-scanning microscope (LSM 510-META; Carl Zeiss, Inc.) under sensi-
tized emission settings. Each image consisted of three channels: donor 
(CFP) channel; acceptor (YFP) channel; and FRET channel (excitation wave-
length 458 nm and emission ﬁ  lters LP 530). For each experiment, appropri-
ate controls transfected with either donor alone (CFP-PP2A) or acceptor 
alone (YFP-ezrin) were prepared. Cells showing similar ﬂ  uorescence inten-
sity for the donor (CFP) and acceptor (YFP) were selected for analysis. FRET 
efﬁ  ciency was determined using the LSM Image Examiner software (Carl 
Zeiss, Inc.). FRET pictures were normalized for the FRET efﬁ  ciencies in the 
respective setting as indicated by the accompanying rainbow scale (FRET 
efﬁ  ciency ranges from blue/0 to red/100%). 
  Preparation of cytosolic/membrane fractions 
  Cell pellets from the different treatment groups were lysed by sonication in 
a buffer consisting of 10 mM Hepes, 150 mM NaCl, 1 mM EDTA, pH 7.4, 
5 mM sodium ﬂ  uoride, 1.75 mM sodium orthovanadate, 1 mM phenyl-
methylsulfonyl ﬂ  uoride, 20 mM     -glycerol phosphate, 10   μ  g/ml leupeptin, 
10   μ  g/ml aprotinin, and 1   μ  M microcystin. Homogenates were cleared of 
debris by centrifugation at 500   g   at 4  °  C. Samples of the postnuclear super-
natants were supplied with sample buffer and corresponded to total cell 349  INACTIVATION OF EZRIN BY STRESS-INDUCED CERAMIDE   •   ZEIDAN ET AL.
myelinase to Bid-mediated caspase-9 and -3 activation.       Cell Death Differ.   
 11 : 550  –  563 .    
   Herr ,   I. ,   D.    Wilhelm ,   T.    Bohler ,   P.    Angel ,  and   K.M.    Debatin .   1997 .   Activation 
of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-
induced apoptosis.       EMBO J.     16 : 6200  –  6208 .    
   Hu ,   W. ,   R.    Xu ,   G.    Zhang ,   J.    Jin ,   Z.M.    Szulc ,   J.    Bielawski ,   Y.A.    Hannun ,   L.M.  
 Obeid ,  and   C.    Mao .   2005 .   Golgi  fragmentation  is  associated  with  ceramide-
induced cellular effects.       Mol. Biol. Cell   .    16 : 1555  –  1567 .    
   Kondo ,   T. ,   K.    Takeuchi ,   Y.    Doi ,   S.    Yonemura ,   S.    Nagata ,  and   S.    Tsukita .   1997 . 
  ERM (ezrin/radixin/moesin)-based molecular mechanism of microvillar 
breakdown at an early stage of apoptosis.       J. Cell Biol.     139 : 749  –  758 .    
   Kruidering ,   M. ,   B.    van  de  Water ,  Y.    Zhan ,   J.J.    Baelde ,   E.    Heer ,   G.J.    Mulder ,   J.L.  
 Stevens ,  and   J.F.    Nagelkerke .   1998.     Cisplatin effects on F-actin and ma-
trix proteins precede renal tubular cell detachment and apoptosis in vitro.   
  Cell Death Differ.     5 : 601 – 614 .  
   Lacour ,   S. ,   A.    Hammann ,   S.    Grazide ,   D.    Lagadic-Gossmann ,   A.    Athias ,   O.  
 Sergent ,   G.    Laurent ,   P.    Gambert ,   E.    Solary ,  and   M.T.    Dimanche-Boitrel  . 
  2004  .   Cisplatin-induced CD95 redistribution into membrane lipid rafts of 
HT29 human colon cancer cells.       Cancer Res.     64 : 3593  –  3598 .    
   Levade ,   T. ,  and   J.P.    Jaffrezou .   1999 .   Signalling  sphingomyelinases:  which, 
where, how and why?       Biochim. Biophys. Acta   .    1438 : 1  –  17 .  
   Lovat ,   P.E. ,   F.    Di  Sano ,   M.    Corazzari ,   B.    Fazi ,   R.P.    Donnorso ,   A.D.    Pearson , 
 A.G.    Hall ,   C.P.    Redfern ,  and   M.    Piacentini .   2004 .   Gangliosides  link  the 
acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxy-
genase-dependent apoptosis of neuroblastoma in response to fenretinide.   
  J. Natl. Cancer Inst.     96 : 1288  –  1299 .  
   Luciani ,   F. ,   A.    Molinari ,   F.    Lozupone ,   A.    Calcabrini ,   L.    Lugini ,   A.    Stringaro , 
 P.    Puddu ,   G.    Arancia ,   M.    Cianfriglia ,  and   S.    Fais .   2002 .   P-glycoprotein-
actin association through ERM family proteins: a role in P-glycoprotein 
function in human cells of lymphoid origin.       Blood   .    99 : 641  –  648 .    
   Maceyka ,   M. ,   S.G.    Payne ,   S.    Milstien ,  and   S.    Spiegel .   2002 .   Sphingosine 
kinase, sphingosine-1-phosphate, and apoptosis.       Biochim. Biophys. Acta   .  
 1585 : 193  –  201 .  
   Mandic ,   A. ,   J.    Hansson ,   S.    Linder ,  and   M.C.    Shoshan .   2003 .   Cisplatin  induces 
endoplasmic reticulum stress and nucleus-independent apoptotic signaling.   
  J. Biol. Chem.     278 : 9100  –  9106 .    
   Marchesini ,   N. ,  and   Y.A.    Hannun .   2004 .   Acid  and  neutral  sphingomyelinases: 
roles and mechanisms of regulation.       Biochem. Cell Biol.     82 : 27  –  44 .    
   Marchesini ,   N. ,   C.    Luberto ,  and   Y.A.    Hannun .   2003 .   Biochemical  properties  of 
mammalian neutral sphingomyelinase 2 and its role in sphingolipid 
metabolism.     J. Biol. Chem.     278 : 13775  –  13783 .    
   Meisinger ,   J. ,   S.    Patel ,   K.    Vellody ,   R.    Bergstrom ,   J.    Benefi   eld ,   Y.    Lozano ,  and 
 M.R.    Young .   1997 .   Protein  phosphatase-2A  association  with  micro-
tubules and its role in restricting the invasiveness of human head and neck 
squamous cell carcinoma cells.       Cancer Lett.     111 : 87  –  95 .    
   Metz ,   R.J. ,   K.    Vellody ,   S.    Patel ,   R.    Bergstrom ,   J.    Meisinger ,   J.    Jackson ,   M.A.  
 Wright ,  and   M.R.   Young .   1996 .   Vitamin  D3  and  ceramide  reduce  the  in-
vasion of tumor cells through extracellular matrix components by elevat-
ing protein phosphatase-2A.       Invasion Metastasis   .    16 : 280  –  290 .  
   Ogretmen ,   B. ,  and  Y.A.    Hannun .   2004 .   Biologically  active  sphingolipids  in  can-
cer pathogenesis and treatment.       Nat. Rev. Cancer   .    4 : 604  –  616 .    
   Panigone ,   S. ,   R.    Bergomas ,   E.    Fontanella ,   A.    Prinetti ,   K.    Sandhoff ,   G.A.  
 Grabowski ,  and   D.    Delia .   2001 .   Up-regulation  of  prosaposin  by  the  ret-
inoid HPR and its effect on ceramide production and integrin receptors.   
  FASEB J.     15 : 1475  –  1477 .  
   Pettus ,   B.J. ,   C.E.    Chalfant ,  and  Y.A.    Hannun .   2002 .   Ceramide  in  apoptosis:  an  over-
view and current perspectives.       Biochim. Biophys. Acta   .    1585 : 114  –  125 .  
   Prag ,   S. ,   M.    Parsons ,   M.D.    Keppler ,   S.M.    Ameer-Beg ,   P.    Barber ,   J.    Hunt ,   A.J.  
 Beavil ,   R.    Calvert ,   M.    Arpin ,   B.    Vojnovic ,  and   T.    Ng .   2007 .   Activated 
ezrin promotes cell migration through recruitment of the GEF Dbl to lipid 
rafts and preferential downstream activation of Cdc42.     Mol. Biol. Cell.   
 18 : 2935 – 2948 .  
   Prinetti ,  A. ,   D.    Millimaggi ,   S.    D ’ Ascenzo ,   M.    Clarkson ,  A.    Bettiga ,  V.    Chigorno , 
 S.    Sonnino ,   A.    Pavan ,  and   V.    Dolo .   2006 .   Lack  of  ceramide  generation 
and altered sphingolipid composition are associated with drug resistance 
in human ovarian carcinoma cells.       Biochem. J.     395 : 311  –  318 .    
   Rahmani ,   M. ,   E.    Reese ,  Y.    Dai ,   C.    Bauer ,   S.G.    Payne ,   P.    Dent ,   S.    Spiegel ,  and   S.  
  Grant  .   2005  .   Coadministration of histone deacetylase inhibitors and peri-
fosine synergistically induces apoptosis in human leukemia cells through 
Akt and ERK1/2 inactivation and the generation of ceramide and reactive 
oxygen species.       Cancer Res.     65 : 2422  –  2432 .    
   R u v o l o  ,    P. P.     2003  .   Intracellular signal transduction pathways activated by cer-
amide and its metabolites.       Pharmacol. Res.     47 : 383  –  392 .    
   Safaei ,   R. ,   K.    Katano ,   B.J.    Larson ,   G.    Samimi ,  A.K.    Holzer ,  W.    Naerdemann ,   M.  
 Tomioka ,   M.    Goodman ,  and   S.B.    Howell .   2005 .   Intracellular  localization 
and traffi  cking of fl  uorescein-labeled cisplatin in human ovarian carci-
noma cells.       Clin. Cancer Res.     11 : 756  –  767 .  
Submitted:   11 May 2007 
Accepted:   25 March 2008 
  References 
   Bezombes ,   C. ,   G.    Laurent ,  and   J.P.    Jaffrezou .   2003 .   Implication  of  raft  micro-
domains in drug induced apoptosis.       Curr. Med. Chem. Anti-cancer. Agents   .  
 3 : 263  –  270 .    
   Bielawski ,   J. ,   Z.M.    Szulc ,  Y.A.    Hannun ,  and   A.    Bielawska .   2006 .   Simultaneous 
quantitative analysis of bioactive sphingolipids by high-performance liq-
uid chromatography-tandem mass spectrometry.       Methods   .    39 : 8   
   Bijman ,   M.N. ,   G.P.    van  Nieuw  Amerongen ,   N.    Laurens ,   V.W.    van  Hinsbergh , 
and   E.    Boven .   2006.    Microtubule-targeting  agents  inhibit  angiogenesis  at 
subtoxic concentrations, a process associated with inhibition of Rac1 and 
Cdc42 activity and changes in the endothelial cytoskeleton.     Mol. Cancer 
Ther.    5 : 2348 – 2357 .  
   Bretscher ,   A. ,   K.    Edwards ,  and   R.G.    Fehon .   2002 .   ERM  proteins  and  merlin: 
integrators at the cell cortex.       Nat. Rev. Mol. Cell Biol.     3 : 586  –  599 .    
   Brown ,   M.J. ,   R.    Nijhara ,   J.A.    Hallam ,   M.    Gignac ,   K.M.   Yamada ,   S.L.    Erlandsen , 
 J.    Delon ,   M.    Kruhlak ,  and   S.    Shaw .   2003 .   Chemokine  stimulation  of 
human peripheral blood T lymphocytes induces rapid dephosphorylation 
of ERM proteins, which facilitates loss of microvilli and polarization.   
  Blood   .    102 : 3890  –  3899 .    
   Calderon ,   R.O. ,  and   G.H.    DeVries .   1997 .   Lipid  composition  and  phospholipid 
asymmetry of membranes from a Schwann cell line.       J. Neurosci. Res.   
 49 : 372  –  380 .    
   Chalfant ,   C.E. ,   K.    Kishikawa ,   M.C.    Mumby ,   C.    Kamibayashi ,  A.    Bielawska ,  and 
 Y.A.    Hannun .   1999 .   Long  chain  ceramides  activate  protein  phosphatase-1 
and protein phosphatase-2A. Activation is stereospecifi  c and regulated by 
phosphatidic acid.       J. Biol. Chem.     274 : 20313  –  20317 .    
   Chalfant ,   C.E. ,   B.    Ogretmen ,   S.    Galadari ,   B.J.    Kroesen ,   B.J.    Pettus ,  and   Y.A.  
  Hannun  .   2001  .   FAS activation induces dephosphorylation of SR proteins; 
dependence on the de novo generation of ceramide and activation of pro-
tein phosphatase 1.       J. Biol. Chem.     276 : 44848  –  44855 .    
   Chalfant ,   C.E. ,   Z.    Szulc ,   P.    Roddy ,   A.    Bielawska ,  and   Y.A.    Hannun .   2004 .   The 
structural requirements for ceramide activation of serine-threonine pro-
tein phosphatases.       J. Lipid Res.     45 : 496  –  506 .    
   Charruyer ,  A. ,  S.   Grazide ,  C.   Bezombes ,  S.   Muller ,  G.   Laurent , and  J.P.   Jaffrezou . 
  2005  .   UV-C light induces raft-associated acid sphingomyelinase and JNK 
activation and translocation independently on a nuclear signal.       J. Biol. 
Chem.     280 : 19196  –  19204 .    
   Curto ,   M. ,  and   A.I.    McClatchey .   2004 .   Ezrin   …   a metastatic detERMinant?   
  Cancer Cell   .    5 : 113  –  114 .    
   Di  Bartolomeo ,   S. ,  and   A.    Spinedi .   2002 .   Ordering  ceramide-induced  cell 
detachment and apoptosis in human neuroepithelioma.       Neurosci. Lett.   
 334 : 149  –  152 .    
   Donati ,   C. ,  and   P.    Bruni .   2006 .   Sphingosine  1-phosphate  regulates  cytoskeleton 
dynamics: implications in its biological response.       Biochim. Biophys. 
Acta   .    1758 : 2037  –  2048 .    
   Emert-Sedlak ,   L. ,   S.    Shangary ,   A.    Rabinovitz ,   M.B.    Miranda ,   S.M.    Delach , 
and   D.E.     Johnson  .   2005  .   Involvement of cathepsin D in chemotherapy-
induced cytochrome c release, caspase activation, and cell death.       Mol. 
Cancer Ther.     4 : 733  –  742 .    
   Fievet ,  B.T. ,  A.   Gautreau ,  C.   Roy ,  L.   Del Maestro ,  P.   Mangeat ,  D.   Louvard , and  M.  
  Arpin  .   2004  .   Phosphoinositide binding and phosphorylation act sequen-
tially in the activation mechanism of ezrin.       J. Cell Biol.     164 : 653  –  659 .    
   Fievet ,   B. ,   D.    Louvard ,  and   M.     Arpin  .   2007  .   ERM proteins in epithelial cell orga-
nization and functions.       Biochim. Biophys. Acta   .    1773 : 653  –  660 .  
   Gautreau ,  A. ,   D.    Louvard ,  and   M.   Arpin .   2000 .   Morphogenic  effects  of  ezrin  re-
quire a phosphorylation-induced transition from oligomers to monomers 
at the plasma membrane.       J. Cell Biol.     150 : 193  –  203 .    
   Hanada ,   K. ,   T.    Hara ,   M.    Fukasawa ,   A.    Yamaji ,   M.    Umeda ,  and   M.    Nishijima . 
  1998  .   Mammalian cell mutants resistant to a sphingomyelin-directed 
cytolysin. Genetic and biochemical evidence for complex formation of 
the LCB1 protein with the LCB2 protein for serine palmitoyltransferase.     
  J. Biol. Chem.     273 : 33787  –  33794 .    
   Heinrich ,   M. ,   M.    Wickel ,   W.    Schneider-Brachert ,   C.    Sandberg ,   J.    Gahr ,   R.  
 Schwandner ,   T.    Weber ,   P.    Saftig ,   C.    Peters ,   J.    Brunner ,   et  al .   1999 . 
  Cathepsin D targeted by acid sphingomyelinase-derived ceramide.       EMBO J.   
 18 : 5252  –  5263 .    
   Heinrich ,   M. ,   M.    Wickel ,   S.    Winoto-Morbach ,   W.    Schneider-Brachert ,   T.    Weber , 
 J.   Brunner ,  P.   Saftig ,  C.   Peters ,  M.   Kronke , and  S.   Schutze .  2000 .  Ceramide 
as an activator lipid of cathepsin D.       Adv. Exp. Med. Biol.     477 : 305  –  315 .  
   Heinrich ,   M. ,   J.    Neumeyer ,   M.    Jakob ,   C.    Hallas ,   V.    Tchikov ,   S.    Winoto-
Morbach ,   M.    Wickel ,   W.    Schneider-Brachert ,   A.    Trauzold ,   A.    Hethke , 
and   S.    Schutze .   2004 .   Cathepsin  D  links  TNF-induced  acid  sphingo-JCB • VOLUME 181 • NUMBER 2 • 2008  350 
   Stover ,   T.C. ,  A.    Sharma ,   G.P.    Robertson ,  and   M.    Kester .   2005 .   Systemic  delivery 
of liposomal short-chain ceramide limits solid tumor growth in murine 
models of breast adenocarcinoma.       Clin. Cancer Res.     11 : 3465  –  3474 .    
   Toman ,   R.E. ,   S.G.    Payne ,   K.R.    Watterson ,   M.    Maceyka ,   N.H.    Lee ,   S.    Milstien , 
 J.W.    Bigbee ,  and   S.    Spiegel .   2004 .   Differential  transactivation  of  sphin-
gosine-1-phosphate receptors modulates NGF-induced neurite extension.   
  J. Cell Biol.     166 : 381  –  392 .    
   van Helvoort ,  A. ,  M.L.   Giudici ,  M.   Thielemans , and  G.   van Meer .  1997 .  Transport 
of sphingomyelin to the cell surface is inhibited by brefeldin A and in 
mitosis, where C6-NBD-sphingomyelin is translocated across the plasma 
membrane by a multidrug transporter activity.       J. Cell Sci.     110 : 75  –  83 .  
   Xu ,   L. ,  and   X.    Deng .   2006 .   Suppression  of  cancer  cell  migration  and  invasion  by 
protein phosphatase 2A through dephosphorylation of mu- and m-calpains.   
  J. Biol. Chem.     281 : 35567  –  35575 .    
   Yoshinaga-Ohara ,   N. ,   A.    Takahashi ,   T.    Uchiyama ,  and   M.    Sasada .   2002 . 
  Spatiotemporal regulation of moesin phosphorylation and rear release by 
Rho and serine/threonine phosphatase during neutrophil migration.       Exp. 
Cell Res.     278 : 112  –  122 .    
   Zeidan ,   Y.H. ,  and   Y.A.    Hannun .   2007 .   Activation  of  acid  sphingomyelinase 
by  protein  kinase  C { delta } -mediated  phosphorylation.     J. Biol. Chem.   
 282 : 11549  –  11561 .    
   Zeidan ,   Y.H. ,   B.J.    Pettus ,   S.    Elojeimy ,   T.     Taha ,   L.M.    Obeid ,   T.    Kawamori ,   J.S.  
 Norris ,  and   Y.A.    Hannun .   2006 .   Acid  ceramidase  but  not  acid  sphingo-
myelinase is required for tumor necrosis factor-  {  alpha  }  -induced PGE2 
production.     J. Biol. Chem.     281 : 24695  –  24703 .                